Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial-Reference-Cited by-同舟云学术

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Published:2017-04 Issue:4 Volume:18 Page:464-472
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Schreuer Max,Jansen Yanina,Planken Simon,Chevolet Ines,Seremet Teofila,Kruse Vibeke,Neyns Bart

Publisher

Elsevier BV

Subject

Oncology

Reference41 articles.

1. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis;Houben;J Carcinog,2004

2. Distinct sets of genetic alterations in melanoma;Curtin;N Engl J Med,2005

3. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

5. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors;Oncotarget;2024-07-17

2. Patient-derived melanoma models;Pathology - Research and Practice;2024-07

3. Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies;Cancer Medicine;2024-06

4. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma;European Journal of Cancer;2024-05

5. Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report;Journal of Gastrointestinal Oncology;2024-04